Skip to main content
Dryad logo

Hematoma expansion shift analysis to assess acute intracerebral hemorrhage treatments

Citation

Yogendrakumar, Vignan et al. (2021), Hematoma expansion shift analysis to assess acute intracerebral hemorrhage treatments, Dryad, Dataset, https://doi.org/10.5061/dryad.sn02v6x3z

Abstract

Objective: Hematoma expansion (HE) is commonly analyzed as a dichotomous outcome in intracerebral hemorrhage (ICH) trials.  In this proof-of-concept study, we propose a “HE shift” analysis model as a method to improve the evaluation of candidate ICH therapies.

Methods: Using data from the Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-2) trial, we performed HE shift analysis in response to intensive blood pressure lowering by generating polychotomous strata based on a) previously established HE definitions, b) percentile/absolute quartiles of hematoma volume change, and c) quartiles of 24-hour follow-up hematoma volumes. The relationship between blood pressure treatment and HE shift was explored using proportional odds models.

Results: The primary analysis population included 863 patients. In both treatment groups, approximately one-third of patients exhibited no HE. Using a trichotomous HE stratification, the highest strata of ≥33% revealed a 5.8% reduction in hematoma growth for those randomized to intensive therapy (aOR: 0.77 [95% CI: 0.60-0.99]). Using percentile quartiles of hematoma volume change, we observed a favorable shift to reduce growth in patients treated with intensive therapy: aOR: 0.73 (0.57-0.93). Similarly, in a tetrachotomous analysis of 24-hour follow-up hematoma volumes, shifts in the highest stratum (> 21.9 mL) was most notable.

Conclusions: Our findings suggest that intensive blood pressure reduction may preferentially mitigate growth in patients at risk of high volume HE. A shift analysis model of HE provides additional insights into the biological effects of a given therapy and may be an additional way to assess hemostatic agents in future studies.

Registration: ClinicalTrials.gov Identifier: NCT01176565